giovanna.poce@uniroma1.it's picture

Lazio zona rossa: da lunedì 15 marzo 2021 è sospesa la frequenza delle lezioni in modalità mista. Le lezioni proseguiranno esclusivamente a distanza 

 

 

Le lezioni del corso di Analisi dei Medicinali I (M-Z) continuano con il seguente orario in modalità esclusivamente a distanza: 

 

Giorno

Ora

Link per seguire da remoto

Mercoledì

15.00-17.00

https://meet.google.com/mvm-rfbo-udc

Giovedì

15.00-17.00

https://meet.google.com/oyg-ibji-ozh

 

Venerdì

 

13.00-15.00

https://meet.google.com/fhh-doqi-vng

 

 

 

 

 

 

 

 

 

Si rammenta che la frequenza è obbligatoria.

Giovedì 10.00-11.00

Stanza 202, II piano, edificio CU019

Education

03/2008: PhD
DEPARTMENT OF CHEMISTRY AND TECHNOLOGY OF DRUGS, SAPIENZA UNIVERSITY OF ROME, Rome, Italy, Group of Professor Giulio Cesare Porretta
Ph.D. in Medicinal Chemistry
Thesis title: New Pyrrole Derivatives of BM212: a New Class of Antimycobacterial Agents. Design, Synthesis, Biological Evaluation and Study of their Mode of Action.

03/2004: Master Degree
Faculty of Pharmacy, SAPIENZA UNIVERSITY OF ROME, Rome, Italy
Master Degree in Pharmaceutical Chemistry and Technology under the supervision of Professor Giulio Cesare Porretta. Thesis Title: Synthesis and Structure-Activity Relationships of Novel 1,5-Diarylpyrroles Related to BM212.

Experiences and Titles

03/08/2016-30/08/2016: Visiting Academic
SCHOOL OF BIOMEDICAL SCIENCES, UNIVERSITY OF CAPE TOWN, Cape Town, South Africa.

21/01/2015: Abilitazione Scientifica Nazionale a Professore di II fascia (CHIM/08)

10/2014-PRESENT: Ricercatore (RTDA)

DEPARTMENT OF CHEMISTRY AND TECHNOLOGY OF DRUGS, SAPIENZA UNIVERSITY OF ROME, Rome, Italy.
09/2012 09/2014: Research Associate

DEPARTMENT OF CHEMISTRY AND TECHNOLOGY OF DRUGS, SAPIENZA UNIVERSITY OF ROME, Rome, Italy, Group of Professor Mariangela Biava
10/2010 - 08/2012: Visiting Scientist

DEPARTMENT OF IMMUNOLOGY AND INFECTIOUS DISEASES, HARVARD SCHOOL OF PUBLIC HEALTH, Boston, United States, Group of Professor Eric J. Rubin

11/2009 - 09/2010: Post-doc
DEPARTMENT OF CHEMISTRY AND TECHNOLOGY OF DRUGS, SAPIENZA UNIVERSITY OF ROME, Rome, Italy, Group of Professor Mariangela Biava

04/2009 - 10/2009: Academic Visitor
DEPARTMENT OF CHEMISTRY, UNIVERSITY OF OXFORD, Oxford, United Kingdom, Group of Professor Steve G. Davies

04/2008 03/2009: Post-doc
DEPARTMENT OF CHEMISTRY AND TECHNOLOGY OF DRUGS, SAPIENZA UNIVERSITY OF ROME, Rome, Italy, Group of Professor Mariangela Biava

Teaching activities

03/2015-PRESENT:
FACULTY OF PHARMACY AND MEDICINE, SAPIENZA UNIVERSITY OF ROME, Rome, Italy
Teaching third year students of Pharmacy course (Analisi dei Medicinali I)

10/2008 10/2014:
FACULTY OF PHARMACY AND MEDICINE, SAPIENZA UNIVERSITY OF ROME, Rome, Italy
Teaching Assistant in practical analytical chemistry for training forth year undergraduate students in Pharmacy.

2009-PRESENT:
DEPARTMENT OF CHEMISTRY, SAPIENZA UNIVERSITY OF ROME, Rome, Italy
Teaching II level Master Sostanze Organiche Naturali

Publications in peer reviewed journals

Xu, Z.; Poce, G.; Chng, Shu-Sin. MmpL3 is the Inner Membrane Flippase for Trehalose Monomycolate in Mycobacteria. Nature. Submitted for publication.

Poce, G.*; Cocozza, M.; Consalvi, S.; Venditti, G.; Fernandez-Menendez, R.; Bates, R. H.; Barros Aguirre, D.; Ballell, L.; De Logu, A.; Vistoli, G.; Biava, M. BM635 Analogues with Improved Drug-like Properties. PlosOne Submitted for publication.

Venditti, G.; Poce, G.; Consalvi, S.; Biava, M. 1,5-Diarylpyrroles as Potent Antitubercular and Anti-Inflammatory Agents. Chem. Heterocycl. Comp. 2017, 53, 281-291.

Poce, G.*; Consalvi, S.; Cocozza, M.; Fernandez-Menendez, R.; Bates, R. H.; Ortega Muro, F.; Barros Aguirre, D.; Ballell, L.; Biavaa, M. Pharmaceutical Salt of BM635 with Improved Bioavailability. Eur. J. Pharm. Sci. 2017, 99, 17-23.

Poce, G.*; Consalvi, S.; Biava, M. MmpL3 Inhibitors: Diverse Chemical Scaffolds Inhibit the Same Target. Mini Rev. Med. Chem. 2016, 16, 1274-1283.

Di Capua, A.; Sticozzi, C.; Brogi, S.; Brindisi, M.; Cappelli, A.; Sautebin, L.; Rossi, A.; Pace, S.; Ghelardini, C.; Di Cesare Mannelli, L.; Valacchi, G.; Giorgi, G.; Giordani, A.; Poce, G.; Biava, M.; Anzini, M. Synthesis and Biological Evaluation of Fluorinated 1,5-Diarylpyrrole-3-Alkoxyethyl Ether Derivatives as Selective COX-2 Inhibitors Endowed with Anti-Inflammatory Activity. Eur. J. Med. Chem. 2016, 109, 99 106.

Consalvi, S.; Biava, M.; Poce, G. COX Inhibitors: A Patent Review (2011 2014). Expert Opin. Ther. Pat. 2015, 25,1357-1371

Poce, G.; Biava, M. Overcoming Drug Resistance for Tuberculosis. Future Microbiol. 2015, 10 (11), 1735 1741.

Piccaro, G.; Poce, G.; Biava, M.; Giannoni, F.; Fattorini, L. Activity of Lipophilic and Hydrophilic Drugs against Dormant and Replicating Mycobacterium Tuberculosis. J. Antibiot. 2015, 68, 711-714.

Dragset, M. S.; Poce, G.; Alfonso, S.; Padilla-Benavides, T.; Ioerger, T. R.; Kaneko, T.; Sacchettini, J. C.; Biava, M.; Parish, T.; Argüello, J. M.; Steigedal, M.; Rubin, E. J. A Novel Antimycobacterial Compound Acts as an Intracellular Iron Chelator. Antimicrob. Agents Chemother. 2015, 59, 2256-2264.

Consalvi, S.; Alfonso, S.; Di Capua, A.; Poce, G.; Pirolli, A.; Sabatino, M.; Ragno, R.; Anzini, M.; Sartini, S.; La Motta, C.; Di Cesare Mannelli, L.; Ghelardini, C.; Biava, M. Synthesis, Biological Evaluation and Docking Analysis of a New Series of Methylsulfonyl and Sulfamoyl Acetamides and Ethyl Acetates as Potent COX-2 Inhibitors. Bioorg. Med. Chem. 2015, 23 (4), 810 820.

Poce, G.*; Cocozza, M.; Consalvi, S.; Biava, M. SAR Analysis of New Anti-TB Drugs Currently in Pre-Clinical and Clinical Development. Eur. J. Med. Chem. 2014, 86, 335 351.

Biava, M.; Battilocchio, C.; Poce, G.; Alfonso, S.; Consalvi, S.; Di Capua, A.; Calderone, V.; Martelli, A.; Testai, L.; Sautebin, L.; Rossi, A.; Ghelardini, C.; Di Cesare Mannelli, L.; Giordani, A.; Persiani, S.; Colovic, M.; Dovizio, M.; Patrignani, P.; Anzini, M. Enhancing the Pharmacodynamic Profile of a Class of Selective COX-2 Inhibiting Nitric Oxide Donors. Bioorg. Med. Chem. 2014, 22 (2), 772 786.

Martelli, A.; Testai, L.; Anzini, M.; Cappelli, A.; Di Capua, A.; Biava, M.; Poce, G.; Consalvi, S.; Giordani, A.; Caselli, G.; Rovati, L.; Ghelardini, C.; Patrignani, P.; Sautebin, L.; Breschi, M. C.; Calderone, V. The Novel Anti-Inflammatory Agent VA694, Endowed with Both NO-Releasing and COX2-Selective Inhibiting Properties, Exhibits NO-Mediated Positive Effects on Blood Pressure, Coronary Flow and Endothelium in an Experimental Model of Hypertension and Endothelial Dysfunction. Pharmacol. Res. Off. J. Ital. Pharmacol. Soc. 2013, 78, 1 9.

Baiocco, P.; Poce, G.; Alfonso, S.; Cocozza, M.; Porretta, G. C.; Colotti, G.; Biava, M.; Moraca, F.; Botta, M.; Yardley, V.; Fiorillo, A.; Lantella, A.; Malatesta, F.; Ilari, A. Inhibition of Leishmania Infantum Trypanothione Reductase by Azole-Based Compounds: A Comparative Analysis with Its Physiological Substrate by X-Ray Crystallography. ChemMedChem 2013, 8 (7), 1175 1183.

Battilocchio, C.; Poce, G.; Alfonso, S.; Porretta, G. C.; Consalvi, S.; Sautebin, L.; Pace, S.; Rossi, A.; Ghelardini, C.; Di Cesare Mannelli, L.; Schenone, S.; Giordani, A.; Di Francesco, L.; Patrignani, P.; Biava, M. A Class of Pyrrole Derivatives Endowed with Analgesic/anti-Inflammatory Activity. Bioorg. Med. Chem. 2013, 21 (13), 3695 3701.

Anzini, M.; Di Capua, A.; Valenti, S.; Brogi, S.; Rovini, M.; Giuliani, G.; Cappelli, A.; Vomero, S.; Chiasserini, L.; Sega, A.; Poce, G.; Giorgi, G.; Calderone, V.; Martelli, A.; Testai, L.; Sautebin, L.; Rossi, A.; Pace, S.; Ghelardini, C.; Di Cesare Mannelli, L.; Benetti, V.; Giordani, A.; Anzellotti, P.; Dovizio, M.; Patrignani, P.; Biava, M. Novel Analgesic/anti-Inflammatory Agents: 1,5-Diarylpyrrole Nitrooxyalkyl Ethers and Related Compounds as Cyclooxygenase-2 Inhibiting Nitric Oxide Donors. J. Med. Chem. 2013, 56 (8), 3191 3206.

Poce, G.*; Bates, R. H.; Alfonso, S.; Cocozza, M.; Porretta, G. C.; Ballell, L.; Rullas, J.; Ortega, F.; De Logu, A.; Agus, E.; La Rosa, V.; Pasca, M. R.; De Rossi, E.; Wae, B.; Franzblau, S. G.; Manetti, F.; Botta, M.; Biava, M. Improved BM212 MmpL3 Inhibitor Analogue Shows Efficacy in Acute Murine Model of Tuberculosis Infection. PloS One 2013, 8 (2), e56980.

Biava, M.; Battilocchio, C.; Poce, G.; Alfonso, S.; Consalvi, S.; Porretta, G. C.; Schenone, S.; Calderone, V.; Martelli, A.; Testai, L.; Ghelardini, C.; Di Cesare Mannelli, L.; Sautebin, L.; Rossi, A.; Giordani, A.; Patrignani, P.; Anzini, M. Improving the Solubility of a New Class of Antiinflammatory Pharmacodynamic Hybrids, That Release Nitric Oxide and Inhibit Cycloxygenase-2 Isoenzyme. Eur. J. Med. Chem. 2012, 58, 287 298.

La Rosa, V.; Poce, G.; Canseco, J. O.; Buroni, S.; Pasca, M. R.; Biava, M.; Raju, R. M.; Porretta, G. C.; Alfonso, S.; Battilocchio, C.; Javid, B.; Sorrentino, F.; Ioerger, T. R.; Sacchettini, J. C.; Manetti, F.; Botta, M.; De Logu, A.; Rubin, E. J.; De Rossi, E. MmpL3 Is the Cellular Target of the Antitubercular Pyrrole Derivative BM212. Antimicrob. Agents Chemother. 2012, 56 (1), 324 331.

Biava, M.; Porretta, G. C.; Poce, G.; Battilocchio, C.; Botta, M.; Marietti, F.; Rovini, M.; Cappelli, A.; Sautebin, L.; Rossi, A.; Pergola, C.; Ghelardini, C.; Galeotti, N.; Makovec, F.; Giordani, A.; Anzellotti, P.; Tacconelli, S.; Patrignani, P.; Anzini, M. Enlarging the NSAIDs Family: Ether, Ester and Acid Derivatives of the 1,5-Diarylpyrrole Scaffold as Novel Anti-Inflammatory and Analgesic Agents. Curr. Med. Chem. 2011, 18 (10), 1540 1554.

Biava, M.; Porretta, G. C.; Poce, G.; Battilocchio, C.; Alfonso, S.; Rovini, M.; Valenti, S.; Giorgi, G.; Calderone, V.; Martelli, A.; Testai, L.; Sautebin, L.; Rossi, A.; Papa, G.; Ghelardini, C.; Di Cesare Mannelli, L.; Giordani, A.; Anzellotti, P.; Bruno, A.; Patrignani, P.; Anzini, M. Novel Analgesic/anti-Inflammatory Agents: Diarylpyrrole Acetic Esters Endowed with Nitric Oxide Releasing Properties. J. Med. Chem. 2011, 54 (22), 7759 7771.

Biava, M.; Porretta, G. C.; Poce, G.; Battilocchio, C.; Alfonso, S.; deLogu, A.; Manetti, F.; Botta, M. Developing Pyrrole-Derived Antimycobacterial Agents: A Rational Lead Optimization Approach. ChemMedChem 2011, 6 (4), 593 599.

Davies, S. G.; Fletcher, A. M.; Hermann, G. J.; Poce, G.; Roberts, P. M.; Smith, A. D.; Sweet, M. J.; Thomson, J. E. Doubly Diastereoselective Conjugate Addition of Enantiopure Lithium Amides to Enantiopure N-Enoyl Oxazolidin-2-Ones: A Mechanistic Probe. Tetrahedron Asymmetry 2010, 21 (13-14), 1635 1648.

Davies, S. G.; Fletcher, A. M.; Kurosawa, W.; Lee, J. A.; Poce, G.; Roberts, P. M.; Thomson, J. E.; Williamson, D. M. One-Pot Conversions of Olefins to Cyclic Carbonates and Secondary Allylic and Homoallylic Amines to Cyclic Carbamates. J. Org. Chem. 2010, 75 (22), 7745 7756.

Biava, M.; Porretta, G. C.; Poce, G.; Battilocchio, C.; Alfonso, S.; Logu, A. D.; Serra, N.; Manetti, F.; Botta, M. Identification of a Novel Pyrrole Derivative Endowed with Antimycobacterial Activity and Protection Index Comparable to that of the Current Antitubercular Drugs Streptomycin and Rifampin. Bioorg. Med. Chem. 2010, 18 (22), 8076 8084.

Biava, M.; Porretta, G. C.; Poce, G.; Battilocchio, C.; Manetti, F.; Botta, M.; Forli, S.; Sautebin, L.; Rossi, A.; Pergola, C.; Ghelardini, C.; Galeotti, N.; Makovec, F.; Giordani, A.; Anzellotti, P.; Patrignani, P.; Anzini, M. Novel Ester and Acid Derivatives of the 1,5-Diarylpyrrole Scaffold as Anti-Inflammatory and Analgesic Agents. Synthesis and in Vitro and in Vivo Biological Evaluation. J. Med. Chem. 2010, 53 (2), 723 733.

Biava, M.; Porretta, G. C.; Poce, G.; De Logu, A.; Meleddu, R.; De Rossi, E.; Manetti, F.; Botta, M. 1,5-Diaryl-2-Ethyl Pyrrole Derivatives as Antimycobacterial Agents: Design, Synthesis, and Microbiological Evaluation. Eur. J. Med. Chem. 2009, 44 (11), 4734 4738.

Poce, G.*; Cesare Porretta, G.; Biava, M. C-9 Alkenylidine Bridged Macrolides: WO2008061189. Enanta Pharmaceuticals, Inc. Expert Opin. Ther. Pat. 2009, 19 (6), 901 906.

Biava, M.; Porretta, G. C.; Poce, G.; Supino, S.; Manetti, F.; Forli, S.; Botta, M.; Sautebin, L.; Rossi, A.; Pergola, C.; Ghelardini, C.; Norcini, M.; Makovec, F.; Giordani, A.; Anzellotti, P.; Cirilli, R.; Ferretti, R.; Gallinella, B.; Torre, F. L.; Anzini, M.; Patrignani, P. Synthesis, in Vitro, and in Vivo Biological Evaluation and Molecular Docking Simulations of Chiral Alcohol and Ether Derivatives of the 1,5-Diarylpyrrole Scaffold as Novel Anti-Inflammatory and Analgesic Agents. Bioorg. Med. Chem. 2008, 16 (17), 8072 8081.

Biava, M.; Porretta, G. C.; Poce, G.; De Logu, A.; Saddi, M.; Meleddu, R.; Manetti, F.; De Rossi, E.; Botta, M. 1,5-Diphenylpyrrole Derivatives as Antimycobacterial Agents. Probing the Influence on Antimycobacterial Activity of Lipophilic Substituents at the Phenyl Rings. J. Med. Chem. 2008, 51 (12), 3644 3648.

Poce, G.*; Zappia, G.; Porretta, G. C.; Botta, B.; Biava, M. New Oxazolidinone Derivatives as Antibacterial Agents with Improved Activity. Expert Opin. Ther. Pat. 2008, 18 (2), 97 121.

Biava, M.; Cirilli, R.; Fares, V.; Ferretti, R.; Gallinella, B.; La Torre, F.; Poce, G.; Porretta, G. C.; Supino, S.; Villani, C. HPLC Enantioseparation and Absolute Configuration of Novel Anti-Inflammatory Pyrrole Derivatives. Chirality 2008, 20 (6), 775 780.

Biava, M.; Porretta, G. C.; Poce, G.; Supino, S.; Forli, S.; Rovini, M.; Cappelli, A.; Manetti, F.; Botta, M.; Sautebin, L.; Rossi, A.; Pergola, C.; Ghelardini, C.; Vivoli, E.; Makovec, F.; Anzellotti, P.; Patrignani, P.; Anzini, M. Cyclooxygenase-2 Inhibitors. 1,5-Diarylpyrrol-3-Acetic Esters with Enhanced Inhibitory Activity toward Cyclooxygenase-2 and Improved Cyclooxygenase-2/cyclooxygenase-1 Selectivity. J. Med. Chem. 2007, 50 (22), 5403 5411.

Biava, M.; Porretta, G. C.; Poce, G.; Supino, S.; Sleiter, G. New Pyrroles with Potential Antimycobacterial, Antifungal and Selective COX-2 Inhibiting Activities. Synthetic Methodologies. Curr. Org. Chem. 2007, 11 (12), 1092 1112.

Biava, M.; Porretta, G. C.; Poce, G.; Supino, S.; Deidda, D.; Pompei, R.; Molicotti, P.; Manetti, F.; Botta, M. Antimycobacterial Agents. Novel Diarylpyrrole Derivatives of BM212 Endowed with High Activity toward Mycobacterium Tuberculosis and Low Cytotoxicity. J. Med. Chem. 2006, 49 (16), 4946 4952.

Biava, M.; Porretta, G. C.; Poce, G.; Deidda, D.; Pompei, R.; Tafi, A.; Manetti, F. Antimycobacterial Compounds. Optimization of the BM 212 Structure, the Lead Compound for a New Pyrrole Derivative Class. Bioorg. Med. Chem. 2005, 13 (4), 1221 1230.

Oral presentations/seminars as invited speaker
Poce, G. Simple Chemistries as Enabling Tool for Advancing TB and Cancer Research. School of Biomedical Sciences, University of Cape Town, Cape Town, South Africa, 24 August 2016. (Seminar)
Poce, G. Towards Tuberculosis Treatment with Novel MmpL3 Inhibitors. Dipartimento di Scienze Farmaceutiche, Università degli Studi di Perugia, 18 March 2014. (Seminar)
Poce, G. BM212-Derived MmpL3 Inhibitors Enabling New Possibilities for the Treatment of TB. Tuberculosis Drug Development, Gordon Research Conference, Barga (LU), 21-26 July 2013. (Keynote)
Poce, G. Hit-to-Lead Development for a New Class of Anti-Mycobacterial Agents. Tres Cantos Open LabFoundation, Tres Cantos, 10 June 2013. (Seminar)
Poce, G.; Porretta, G. C.; De Logu, A.; De Rossi, E.; Rubin, E.J.; Ballel, L.; Botta, M.; Biava, M. 1,5-Diphenyl Pyrroles as New Antimycobacterial Agents. Hit-to-lead Development and Target Validation. COST Action MeetingCM0801, Siena, 29-31 May 2012. (Oral presentation)

Oral presentations
Alfonso, S.; Cocozza, M.; Poce, G.; Porretta, G.C.; Bates, R.H.; Ballel, L.; Rullas, J.; Ortega, F.; De Logu, A.; Agus, A.; De Rossi, E.; Wae, W.; Franzblau, S.G.; Manetti, F.; Botta, M.; Biava, M. MmpL3 Inhibitors Enabling New Possibilities for TB Treatment. XXII National Meeting on Medicinal Chemistry, Rome, 10-13 September 2013.

Biava, M.; Porretta, G.C.; Poce, G.; Alfonso, S.; Battilocchio, C.; De Logu, A.; Manetti, F.; Botta, M. Identification of a New Chemical Series of Potent Antimycobacterial Compounds. XX National Meeting on Medicinal Chemistry, Abano Terme, 12-16 September 2010.
Biava, M.; Porretta, G.C.; Poce, G.; De Logu, A.; Manetti, F.; Botta, M. New Pyrrole Derivatives of BM212: a New Class of Antimycobacterial Agents. Design, Synthesis, Biological Evaluation and Study of Their Mode of Action. NPCFIII, Pisa, 13-14 February 2009.

Session Chairman
Session: Alternative Approaches to Target ID and Drug Discovery. Tuberculosis Drug Development, Gordon-Kenan Research Seminar, Barga (LU), 20-21July 2013.

Selected poster presentations
Poce, G.; Consalvi, S.; Alfonso, S.; Fernandez, R.; Bates, R. H.; Ballell, L.; Biava, M. Pyrazole Analogs of BM635 as Potent Antimycobacterial Agents. Tuberculosis Drug Development, Gordon Research Conference, Girona (Spain), 12-17 July 2015.
Poce, G.; Biava, M.; Porretta, G.C.; Battilocchio, C.; Alfonso, S.; Botta, M.; Javid, B.; Sorrentino, F.; Ioerger, T.R.; Sacchettini, J. R.; Rubin, E. J. BM212 Targets MmpL3.Tuberculosis Drug Development, Gordon Research Conference, Barga (LU), 4-8 July 2011.
Poce, G.; Porretta, G.C.; Borzi, F.; De Logu, A.; De Rossi, E.; Manetti, F.; Botta, M.; Biava, M. New Pyrrole Derivatives of BM212: Lead Compound Optimization Strategy. Tuberculosis Drug Development, Targets, Technologies and Trials. Gordon Conference, Magdalen College, Oxford, 16-21 August 2009.
Poce, G.; Porretta, G.C.; De Logu, A.; De Rossi, E.; Manetti, F.; Botta, M.; Biava, M. BM212 and its Derivatives: Lead Optimization of a New Class of Antimycobacterial Agents. 10th Drug Development Seminar in conjunction with the COST Action CM0801, Rauischholzhausen Castle, 19-21 March 2009.
Biava, M.; Porretta, G.C.; Poce, G.; De Logu, A.; Meleddu, R.; De Rossi, E.; Manetti, F.; Botta, M. Design and Synthesis of 1,5-Diaryl-2-ethyl Pyrrole Derivatives and their Evaluation as Antimycobacterial Agents. XIX National Meeting on Medicinal Chemistry, Verona, 14-18 September 2008.
Biava, M.; Porretta, G.C.; Poce, G.; Giordani, A.; Menziani, C. Design and Synthesis of Novel Diarylpyrroles as p38MAP Kinase Inhibitors. XIX National Meeting on Medicinal Chemistry, Verona, 14-18 September 2008.
Biava, M.; Porretta, G.C.; Poce, G.; De Logu, A.; Manetti, F.; Botta M. New 1,5-diphenyl Pyrrole Derived from BM212: a New Class of Antimycobacterial Agents. Tuberculosis Drug Development. Gordon Research Conference, Oxford, 26-31 August 2007.
Biava, M.; Porretta, G.C.; Poce, G.; Deidda, D.; Pompei, R.; Manetti, F.; Botta, M. Design, Synthesis and Screening of New Antitubercular Agents Derived from BM212. VI Laboratorio di Metodologie Sintetiche in Chimica Farmaceutica, Siena, 11-16 February 2007.
Biava, M.; Porretta, G.C.; Poce, G.; Supino, G.; Deidda, D.; Pompei, R.; Manetti, F.; Botta, M. Synthesis of New Pyrrole Derivatives of BM 212, a Potent Antimycobacterial Compound, XXII Convegno Nazionale della Divisione di Chimica Farmaceutica della SCI, Firenze, 10-15 September 2006.
Biava, M.; Porretta, G.C.; Poce, G.; Tibuzzi, D.; Cappelli, A.; Vomero, S.; Botta, M.; Manetti, F.; Sautebin, L.; Rossi, A.; Makovec, F.; Anzini, M. 1,5-Diarylpyrrole Derivatives as Novel Classes of Active and Selective COX-2 Inhibitors. II Joint Italian-Swiss Meeting on Medicinal Chemistry, Modena, 12-16 September 2005.
Biava, M.; Porretta, G.C.; Poce, G.; Deidda, D.; Pompei, R.; Tafi, A.; Manetti, F. Nuovi Derivati 1,5-Difenilpirrolici Derivati del BM 212 Attivi Come Agenti Antitubercolari. XVII Convegno Nazionale della Divisione di Chimica Farmaceutica della SCI, Pisa, 6-10 September 2004.
Biava, M.; Porretta, G.C.; Poce, G.; Cappelli, A.; Vomero, S.; Botta, M.; Manetti, F.; Giorni, G.; Sautebin, L.; Rossi, A.; Makovec, F.; Anzini, M. 1,5-Diarylpyrrole-3-Acetic Acids and Esters as Novel Classes of Potent and Selective COX-2 Inhibitors. Twelfth FECHEM Conference on Heterocycles in Bio-organic Chemistry, Siena, 20-24 June 2004.

Collaborations
Musa Mhlanga, School of Biomedical Sciences, University of Cape Town, Cape Town, South Africa.
Eric J. Rubin, Harvard University, Boston, US.
George W. Whitesides, Harvard University, Boston, US.
Lluis Ballell, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain.
Celia Goulding, Fort Collins, University of California, Irvine, US.
Chng Shu Sin, National University of Singapore, Singapore, Republic of Singapore.

Course Code Year Course - Attendance
Pharmaceutical chemistry 1049264 2021/2022 Bioinformatics
ANALYSIS OF DRUGS WITH LABORATORY 1026164 2021/2022 Pharmacy
ANALYSIS OF DRUGS WITH LABORATORY 1026164 2020/2021 Pharmacy
ANALYSIS OF DRUGS WITH LABORATORY 1026164 2019/2020 Pharmacy
NATURAL COMPOUND EXTRACTION LABORATORY - ANALYSIS OF MEDICINE AND AROMATIC HERBAL PRODUCTS 1052186 2019/2020 Applied Pharmaceutical Sciences
DRUG EXTRACTION LAB AND PHYTOCHEMISTRY 1047779 2019/2020 Pharmaceutical Chemistry and Technology
ANALYSIS OF DRUGS WITH LABORATORY 1026164 2018/2019 Pharmacy
NATURAL COMPOUND EXTRACTION LABORATORY - ANALYSIS OF MEDICINE AND AROMATIC HERBAL PRODUCTS 1052186 2018/2019 Applied Pharmaceutical Sciences
DRUG EXTRACTION LAB AND PHYTOCHEMISTRY 1047779 2018/2019 Pharmaceutical Chemistry and Technology
ANALYSIS OF DRUGS WITH LABORATORY 1026164 2017/2018 Pharmacy
ANALYSIS OF DRUGS WITH LABORATORY 1026164 2016/2017 Pharmacy
Title Journal Year
Therapeutic potential for coxibs-nitric oxide releasing hybrids in cystic fibrosis EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 2021
Dietary flavonoids: Nano delivery and nanoparticles for cancer therapy SEMINARS IN CANCER BIOLOGY 2020
Sar analysis of small molecules interfering with energy-metabolism in mycobacterium tuberculosis PHARMACEUTICALS 2020
Overcoming drug resistance in TB: An update FUTURE MICROBIOLOGY 2020
Novel therapies for glaucoma: a patent review (2013-2019) EXPERT OPINION ON THERAPEUTIC PATENTS 2019
Mycobacterial tryptophan biosynthesis: a promising target for tuberculosis drug development? BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 2019
Novel pyrazole-containing compounds active against mycobacterium tuberculosis ACS MEDICINAL CHEMISTRY LETTERS 2019
Chocolate consumers and lymphocyte-to-monocyte ratio: a working hypothesis from a preliminary report of a pilot study in celiac subjects ANTIOXIDANTS 2019
In vivo potent BM635 analogue with improved drug-like properties EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 2018
Stimuli-responsive tannin–feIII hybrid microcapsules demonstrated by the active release of an anti-tuberculosis agent CHEMSUSCHEM 2018
1,5-Diarylpyrroles as potent antitubercular and anti-inflammatory agents CHEMISTRY OF HETEROCYCLIC COMPOUNDS 2017
MmpL3 is the flippase for mycolic acids in mycobacteria PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2017
Synthesis and biological evaluation of fluorinated 1,5-diarylpyrrole-3-alkoxyethyl ether derivatives as selective COX-2 inhibitors endowed with anti-inflammatory activity EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 2016
A series of COX-2 inhibitors endowed with NO-releasing properties: synthesis, biological evaluation, and docking analysis CHEMMEDCHEM 2016
MmpL3 inhibitors: diverse chemical scaffolds inhibit the same target MINI-REVIEWS IN MEDICINAL CHEMISTRY 2016
A novel antimycobacterial compound acts as an intracellular iron chelator ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 2015
Activity of lipophilic and hydrophilic drugs against dormant and replicating mycobacterium tuberculosis JOURNAL OF ANTIBIOTICS 2015
COX inhibitors: a patent review (2011 - 2014) EXPERT OPINION ON THERAPEUTIC PATENTS 2015
Department
CHIMICA E TECNOLOGIE DEL FARMACO
SSD

CHIM/08